Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07616271 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on the Effect of Oral Diammonium Glycyrrhizinate in Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy

Name: Study on the Effect of Oral Diammonium Glycyrrhizinate in Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy — clinical trial record (NCT07616271)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2/3

SponsorTongji Hospital

Started2026-05-22

View on ClinicalTrials.gov ↗

Tongji Hospital

197 trials monitored

See 2 trials at risk

Non-Hodgkin Lymphoma

1,512 trials monitored

See 79 trials at risk

DLBCL

648 trials monitored

See 32 trials at risk

The purpose of this study is to evaluate the effect of oral diammonium glycyrrhizinate in reducing toxicity and enhancing efficacy of CAR-T cell therapy in patients with large B-cell lymphoma. Two main questions are addressed: 1) Can oral diammonium glycyrrhizinate reduce the incidence and severity of CRS induced by CAR-T cells? 2) Can oral diammonium glycyrrhizinate synergistically increase the therapeutic efficacy of CAR-T cell therapy?

Trial Details

NCT Number	NCT07616271
Lead Sponsor	Tongji Hospital
Conditions	Patients With Large B-cell Lymphoma Receiving CAR-T Cell Therapy
Enrollment	21 participants
Start Date	2026-05-22
Primary Completion	2029-05-31 (estimated)
Study Completion	2030-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-01